Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies

the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan

研究成果: Article

1 引用 (Scopus)

抄録

Objective: To evaluate clinical links between levels of myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody (ANCA) and relapse in patients with ANCA-associated vasculitis (AAV) using a data set from 2 nationwide prospective cohort studies. Methods: From the cohort studies, MPO-ANCA–positive patients who achieved remission during the 6 months after remission induction therapy were enrolled. We measured MPO-ANCA levels at months 0, 3, 6, 12, 18, 24, and at the time of relapse. The primary outcome measure was relapse. A nested case–control analysis and multivariable analysis were performed to investigate the relationship between ANCA reappearance and relapse. Results: Of 271 patients, 183 were classified as having microscopic polyangiitis, 34 as having granulomatosis with polyangiitis, 15 as having eosinophilic granulomatosis with polyangiitis, and 39 were unclassifiable. The median age was 73 years, and 165 (61%) were female. In 195 patients (72%), MPO-ANCA levels decreased to normal levels within 6 months after commencement of treatment, and MPO-ANCA reappeared in 73 of 181 patients (40%) with complete follow-up data. Reappearance of MPO-ANCA was more frequent in patients with relapse than in 75 age- and sex-matched control patients without relapse (odds ratio 26.2 [95% confidence interval 8.2–101], P < 0.0001) after adjustment for confounding factors. Conclusion: Reappearance of MPO-ANCA could be a clinically useful biomarker for predicting relapse in patients with MPO-ANCA–positive AAV in remission. This suggests that routine MPO-ANCA monitoring should be implemented in this patient population.

元の言語English
ページ(範囲)1626-1633
ページ数8
ジャーナルArthritis and Rheumatology
70
発行部数10
DOI
出版物ステータスPublished - 10-2018

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Vasculitis
Peroxidase
Cohort Studies
Prospective Studies
Recurrence
Antibodies
Granulomatosis with Polyangiitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Microscopic Polyangiitis
Remission Induction
Biomarkers
Odds Ratio
Outcome Assessment (Health Care)
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology

これを引用

the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan (2018). Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. Arthritis and Rheumatology, 70(10), 1626-1633. https://doi.org/10.1002/art.40538
the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan. / Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis : Subgroup Analysis of Nationwide Prospective Cohort Studies. :: Arthritis and Rheumatology. 2018 ; 巻 70, 番号 10. pp. 1626-1633.
@article{adc3b6f8ade742a09ef6d240f3d829fb,
title = "Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies",
abstract = "Objective: To evaluate clinical links between levels of myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody (ANCA) and relapse in patients with ANCA-associated vasculitis (AAV) using a data set from 2 nationwide prospective cohort studies. Methods: From the cohort studies, MPO-ANCA–positive patients who achieved remission during the 6 months after remission induction therapy were enrolled. We measured MPO-ANCA levels at months 0, 3, 6, 12, 18, 24, and at the time of relapse. The primary outcome measure was relapse. A nested case–control analysis and multivariable analysis were performed to investigate the relationship between ANCA reappearance and relapse. Results: Of 271 patients, 183 were classified as having microscopic polyangiitis, 34 as having granulomatosis with polyangiitis, 15 as having eosinophilic granulomatosis with polyangiitis, and 39 were unclassifiable. The median age was 73 years, and 165 (61{\%}) were female. In 195 patients (72{\%}), MPO-ANCA levels decreased to normal levels within 6 months after commencement of treatment, and MPO-ANCA reappeared in 73 of 181 patients (40{\%}) with complete follow-up data. Reappearance of MPO-ANCA was more frequent in patients with relapse than in 75 age- and sex-matched control patients without relapse (odds ratio 26.2 [95{\%} confidence interval 8.2–101], P < 0.0001) after adjustment for confounding factors. Conclusion: Reappearance of MPO-ANCA could be a clinically useful biomarker for predicting relapse in patients with MPO-ANCA–positive AAV in remission. This suggests that routine MPO-ANCA monitoring should be implemented in this patient population.",
author = "{the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan} and Haruki Watanabe and Sada, {Ken Ei} and Yoshinori Matsumoto and Masayoshi Harigai and Koichi Amano and Hiroaki Dobashi and Shouichi Fujimoto and Joichi Usui and Kunihiro Yamagata and Tatsuya Atsumi and Shogo Banno and Takahiko Sugihara and Yoshihiro Arimura and Seiichi Matsuo and Hirofumi Makino and Hitoshi Sugiyama and Yoshinari Takasaki and Akihiro Ishizu and Takao Fujii and Yasunori Okada and Sakae Homma and Naotake Tsuboi and Shunichi Kumagai and Eri Muso and Yohko Murakawa and Hitoshi Hasegawa and Wako Yumura and Hiroaki Matsubara and Masaharu Yoshida and Kensei Katsuoka and Noriyoshi Ogawa and Atsushi Komatsuda and Satoshi Ito and Atsushi Kawakami and Izaya Nakaya and Takao Saito and Takafumi Ito and Nobuhito Hirawa and Masahiro Yamamura and Masaaki Nakano and Kosaku Nitta and Makoto Ogura and Taio Naniwa and Shoichi Ozaki and Junichi Hirahashi and Tatsuo Hosoya and Takashi Wada and Satoshi Horikoshi and Yasushi Kawaguchi and Taichi Hayashi",
year = "2018",
month = "10",
doi = "10.1002/art.40538",
language = "English",
volume = "70",
pages = "1626--1633",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan 2018, 'Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies', Arthritis and Rheumatology, 巻. 70, 番号 10, pp. 1626-1633. https://doi.org/10.1002/art.40538

Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis : Subgroup Analysis of Nationwide Prospective Cohort Studies. / the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan.

:: Arthritis and Rheumatology, 巻 70, 番号 10, 10.2018, p. 1626-1633.

研究成果: Article

TY - JOUR

T1 - Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

T2 - Subgroup Analysis of Nationwide Prospective Cohort Studies

AU - the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan

AU - Watanabe, Haruki

AU - Sada, Ken Ei

AU - Matsumoto, Yoshinori

AU - Harigai, Masayoshi

AU - Amano, Koichi

AU - Dobashi, Hiroaki

AU - Fujimoto, Shouichi

AU - Usui, Joichi

AU - Yamagata, Kunihiro

AU - Atsumi, Tatsuya

AU - Banno, Shogo

AU - Sugihara, Takahiko

AU - Arimura, Yoshihiro

AU - Matsuo, Seiichi

AU - Makino, Hirofumi

AU - Sugiyama, Hitoshi

AU - Takasaki, Yoshinari

AU - Ishizu, Akihiro

AU - Fujii, Takao

AU - Okada, Yasunori

AU - Homma, Sakae

AU - Tsuboi, Naotake

AU - Kumagai, Shunichi

AU - Muso, Eri

AU - Murakawa, Yohko

AU - Hasegawa, Hitoshi

AU - Yumura, Wako

AU - Matsubara, Hiroaki

AU - Yoshida, Masaharu

AU - Katsuoka, Kensei

AU - Ogawa, Noriyoshi

AU - Komatsuda, Atsushi

AU - Ito, Satoshi

AU - Kawakami, Atsushi

AU - Nakaya, Izaya

AU - Saito, Takao

AU - Ito, Takafumi

AU - Hirawa, Nobuhito

AU - Yamamura, Masahiro

AU - Nakano, Masaaki

AU - Nitta, Kosaku

AU - Ogura, Makoto

AU - Naniwa, Taio

AU - Ozaki, Shoichi

AU - Hirahashi, Junichi

AU - Hosoya, Tatsuo

AU - Wada, Takashi

AU - Horikoshi, Satoshi

AU - Kawaguchi, Yasushi

AU - Hayashi, Taichi

PY - 2018/10

Y1 - 2018/10

N2 - Objective: To evaluate clinical links between levels of myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody (ANCA) and relapse in patients with ANCA-associated vasculitis (AAV) using a data set from 2 nationwide prospective cohort studies. Methods: From the cohort studies, MPO-ANCA–positive patients who achieved remission during the 6 months after remission induction therapy were enrolled. We measured MPO-ANCA levels at months 0, 3, 6, 12, 18, 24, and at the time of relapse. The primary outcome measure was relapse. A nested case–control analysis and multivariable analysis were performed to investigate the relationship between ANCA reappearance and relapse. Results: Of 271 patients, 183 were classified as having microscopic polyangiitis, 34 as having granulomatosis with polyangiitis, 15 as having eosinophilic granulomatosis with polyangiitis, and 39 were unclassifiable. The median age was 73 years, and 165 (61%) were female. In 195 patients (72%), MPO-ANCA levels decreased to normal levels within 6 months after commencement of treatment, and MPO-ANCA reappeared in 73 of 181 patients (40%) with complete follow-up data. Reappearance of MPO-ANCA was more frequent in patients with relapse than in 75 age- and sex-matched control patients without relapse (odds ratio 26.2 [95% confidence interval 8.2–101], P < 0.0001) after adjustment for confounding factors. Conclusion: Reappearance of MPO-ANCA could be a clinically useful biomarker for predicting relapse in patients with MPO-ANCA–positive AAV in remission. This suggests that routine MPO-ANCA monitoring should be implemented in this patient population.

AB - Objective: To evaluate clinical links between levels of myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody (ANCA) and relapse in patients with ANCA-associated vasculitis (AAV) using a data set from 2 nationwide prospective cohort studies. Methods: From the cohort studies, MPO-ANCA–positive patients who achieved remission during the 6 months after remission induction therapy were enrolled. We measured MPO-ANCA levels at months 0, 3, 6, 12, 18, 24, and at the time of relapse. The primary outcome measure was relapse. A nested case–control analysis and multivariable analysis were performed to investigate the relationship between ANCA reappearance and relapse. Results: Of 271 patients, 183 were classified as having microscopic polyangiitis, 34 as having granulomatosis with polyangiitis, 15 as having eosinophilic granulomatosis with polyangiitis, and 39 were unclassifiable. The median age was 73 years, and 165 (61%) were female. In 195 patients (72%), MPO-ANCA levels decreased to normal levels within 6 months after commencement of treatment, and MPO-ANCA reappeared in 73 of 181 patients (40%) with complete follow-up data. Reappearance of MPO-ANCA was more frequent in patients with relapse than in 75 age- and sex-matched control patients without relapse (odds ratio 26.2 [95% confidence interval 8.2–101], P < 0.0001) after adjustment for confounding factors. Conclusion: Reappearance of MPO-ANCA could be a clinically useful biomarker for predicting relapse in patients with MPO-ANCA–positive AAV in remission. This suggests that routine MPO-ANCA monitoring should be implemented in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=85052393769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052393769&partnerID=8YFLogxK

U2 - 10.1002/art.40538

DO - 10.1002/art.40538

M3 - Article

AN - SCOPUS:85052393769

VL - 70

SP - 1626

EP - 1633

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -

the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan. Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. Arthritis and Rheumatology. 2018 10;70(10):1626-1633. https://doi.org/10.1002/art.40538